Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer

To evaluate whether pathologic complete response (pCR) to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2) therapy is dependent on the HER2 immunohistochemistry (IHC) score. A total of 181 HER2-positive early breast cancer patients who had received neoadjuvant anti-HER2 therapy were...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hai-long, Chen, Qiang, Deng, Yong-chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568472/
https://www.ncbi.nlm.nih.gov/pubmed/34871229
http://dx.doi.org/10.1097/MD.0000000000027632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568472/
https://www.ncbi.nlm.nih.gov/pubmed/34871229
http://dx.doi.org/10.1097/MD.0000000000027632

Ejemplares similares